Optomed Secures €6 Million Investment, Advances AI Initiatives
December 16, 2025, 9:33 am
Optomed Plc completed a €6.0 million share issue. Funds will accelerate AI development for its Lumo handheld fundus camera. This supports US market entry and global AI service expansion. The move bypasses shareholder pre-emption rights due to speed and market conditions. New shares are registered, trading begins December 15th. Optomed aims to revolutionize eye disease diagnostics with handheld technology and AI. The company focuses on diabetic retinopathy screening in over 60 countries. This financing strengthens its position in the rapidly growing oculomics market. It allows Optomed to ramp up production and pursue FDA clearance for AI-powered features. Alternative financing options were deemed too slow and costly. The share issue involved Finnish institutional and qualified investors. The subscription price was set at €3.40, a slight discount to the market price. This ensures a successful and market-based financing arrangement. The new shares represent approximately 8.2% of Optomed’s total shares post-issue. The company’s chairman highlights the importance of this funding for US expansion and global AI service growth. Optomed’s strategy centers on combining handheld cameras with AI to improve eye disease diagnosis. The company’s focus remains on research and development in Finland and sales through diverse channels. This investment is a key step in realizing that vision. It positions Optomed for continued growth in the competitive oculomics landscape. The company is a leader in handheld fundus camera technology. It is dedicated to transforming eye care through innovation.
---
Optomed Plc recently secured approximately €6.0 million through a directed share issue. The company finalized the offering on December 10, 2025. Funds will fuel growth and expansion initiatives. Specifically, Optomed will advance AI algorithm development. This targets the US market with its Lumo handheld fundus camera.
The Board of Directors authorized the issue. It bypassed pre-emptive shareholder subscription rights. This decision was based on speed and market necessity. Alternative financing options were considered. They were deemed too slow and costly.
Optomed launched Lumo in the third quarter of 2025. Early feedback is positive. Lumo received FDA PJZ classification. This allows US marketing as a Class II fundus camera. However, FDA clearance is needed for AI features. This requires completing clinical trials.
The financing will also support global expansion of AI services. This aligns with Optomed’s overall strategy. The company aims to transform eye disease diagnostics. It combines handheld cameras with artificial intelligence.
A total of 1,760,000 shares were subscribed. The subscription price was €3.40 per share. This represents an 11.1% discount to the closing price on December 10, 2025. Investors include Finnish institutional and qualified investors.
The new shares were registered on December 12, 2025. Optomed now has 21,453,297 shares outstanding. Treasury shares total 22,042. Trading will commence on Nasdaq Helsinki on December 15, 2025.
Petri Salonen, Optomed Chairman, stated the financing supports AI initiatives. It also aids commercialization efforts. The company focuses on rapidly increasing diabetic retinopathy. It operates in over 60 countries.
Optomed is a Finnish medical technology company. It is a leading provider of handheld fundus cameras. The company’s strategy centers on innovation. It aims to improve the diagnostic process for blinding eye diseases. Research and development occur in Finland. Sales are managed through various channels globally. This investment positions Optomed for continued success. It reinforces its commitment to transforming eye care.
---
Optomed Plc recently secured approximately €6.0 million through a directed share issue. The company finalized the offering on December 10, 2025. Funds will fuel growth and expansion initiatives. Specifically, Optomed will advance AI algorithm development. This targets the US market with its Lumo handheld fundus camera.
The Board of Directors authorized the issue. It bypassed pre-emptive shareholder subscription rights. This decision was based on speed and market necessity. Alternative financing options were considered. They were deemed too slow and costly.
Optomed launched Lumo in the third quarter of 2025. Early feedback is positive. Lumo received FDA PJZ classification. This allows US marketing as a Class II fundus camera. However, FDA clearance is needed for AI features. This requires completing clinical trials.
The financing will also support global expansion of AI services. This aligns with Optomed’s overall strategy. The company aims to transform eye disease diagnostics. It combines handheld cameras with artificial intelligence.
A total of 1,760,000 shares were subscribed. The subscription price was €3.40 per share. This represents an 11.1% discount to the closing price on December 10, 2025. Investors include Finnish institutional and qualified investors.
The new shares were registered on December 12, 2025. Optomed now has 21,453,297 shares outstanding. Treasury shares total 22,042. Trading will commence on Nasdaq Helsinki on December 15, 2025.
Petri Salonen, Optomed Chairman, stated the financing supports AI initiatives. It also aids commercialization efforts. The company focuses on rapidly increasing diabetic retinopathy. It operates in over 60 countries.
Optomed is a Finnish medical technology company. It is a leading provider of handheld fundus cameras. The company’s strategy centers on innovation. It aims to improve the diagnostic process for blinding eye diseases. Research and development occur in Finland. Sales are managed through various channels globally. This investment positions Optomed for continued success. It reinforces its commitment to transforming eye care.